ASTELLAS PHARMA

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: -

Established: 2005-01-01

Employees: -

Market Cap: $22.5B

Website: https://www.astellas.com/

Clinical Trials

A Study to Evaluate Dose Responses of Efficacy and Safety of ASP0456 in Patient With Chronic Constipation

Phase 2

Completed

Conditions: Chronic Constipation

Interventions: Drug: ASP0456
Drug: Placebo

First Posted Date: 2015-04-24

Last Posted Date: 2024-10-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 383

Registration Number: NCT02425722

Locations: 🇯🇵
Site: 28, Chiba, Japan
🇯🇵
Site: 36, Aichi, Japan
🇯🇵
Site: 29, Chiba, Japan

and more 47 locations

Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes

Phase 3

Completed

Conditions: Bipolar Depression

Interventions: Drug: FK949E

First Posted Date: 2015-02-12

Last Posted Date: 2024-11-15

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 22

Registration Number: NCT02362412

Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

Phase 3

Completed

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)

Interventions: Drug: Placebo
Drug: linaclotide

First Posted Date: 2014-12-15

Last Posted Date: 2024-10-18

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 500

Registration Number: NCT02316899

Locations: 🇯🇵
Site JP00001, Hokkaido, Japan
🇯🇵
Site JP00048, Aichi, Japan
🇯🇵
Site JP00038, Chiba, Japan

and more 58 locations

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
FLT3-mutated Acute Myeloid Leukemia

Interventions: Drug: Gilteritinib
Drug: Idarubicin
Drug: Cytarabine

First Posted Date: 2014-12-08

Last Posted Date: 2024-11-28

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 97

Registration Number: NCT02310321

Locations: 🇯🇵
Site JP81037, Anjo, Aichi, Japan
🇯🇵
Site JP00003, Nagoya, Aichi, Japan
🇯🇵
Site JP81003, Nagoya, Aichi, Japan

and more 52 locations

A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Peficitinib
Biological: Etanercept

First Posted Date: 2014-12-04

Last Posted Date: 2024-10-28

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 509

Registration Number: NCT02308163

Locations: 🇯🇵
JP00099, Chiyoda, Tokyo, Japan
🇯🇵
JP00018, Fukuoka, Japan
🇯🇵
JP00078, Kawachinagano, Osaka, Japan

and more 150 locations

A Study to Evaluate Efficacy and Safety of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to Methotrexate (MTX) Treatment

Phase 3

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Placebo
Drug: Peficitinib
Drug: Methotrexate

First Posted Date: 2014-12-03

Last Posted Date: 2024-10-28

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 519

Registration Number: NCT02305849

Locations: 🇯🇵
JP00109, Nagoya, Aichi, Japan
🇯🇵
JP00068, Yatomi, Aichi, Japan
🇯🇵
JP00106, Kurume, Fukuoka, Japan

and more 143 locations

The Survey of Ipragliflozin Treatment in Elderly type2 Diabetes Patients

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Suglat®

First Posted Date: 2014-11-21

Last Posted Date: 2015-10-15

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 8687

Registration Number: NCT02297620

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Phase 3

Completed

Conditions: Progressive Metastatic Prostate Cancer

Interventions: Drug: Placebo
Drug: Enzalutamide

First Posted Date: 2014-11-19

Last Posted Date: 2024-12-06

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 395

Registration Number: NCT02294461

Locations: 🇨🇳
CN00115, Beijing, China
🇨🇳
CN00112, Beijing, China
🇨🇳
CN00114, Beijing, China

and more 44 locations

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Phase 4

Completed

Conditions: Overactive Bladder (OAB)

Interventions: Drug: Mirabegron tablet
Drug: Tolterodine capsule
Drug: Solifenacin tablet
Drug: Propiverine tablet
Drug: Imidafenacin tablet

First Posted Date: 2014-11-19

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 649

Registration Number: NCT02294396

Post-Marketing Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Ipragliflozin in Combination With GLP-1 Receptor Agonists in Japanese Patients With Type 2 Diabetes Mellitus (T2DM)

Phase 4

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Ipragliflozin

First Posted Date: 2014-11-17

Last Posted Date: 2024-11-08

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 100

Registration Number: NCT02291874

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy